Lora Fleifel
Lora Fleifel currently serves as the Director of Global Value Access & Pricing Operations Europe for Oncology at Merck where she is committed to improving patient access to healthcare and fostering innovation. With over 15 years of experience in market access across multinational pharmaceutical companies, she possesses extensive expertise in both developing and mature markets.
Lora holds a degree in Pharmacy and a Master’s in Health Economics and Pharmacoeconomics, equipping her with a strong foundation for her work. She specializes in developing pricing, access, and reimbursement strategies throughout the product life cycle, from early product assessment to post-launch strategies. Additionally, she has been actively involved in the Joint Clinical Assessment (JCA) since the publication of the EU HTA regulation, focusing on anticipating the necessary changes for organizational readiness.
Lora Fleifel currently serves as the Director of Global Value Access & Pricing Operations Europe for Oncology at Merck where she is committed to improving patient access to healthcare and fostering innovation. With over 15 years of experience in market access across multinational pharmaceutical companies, she possesses extensive expertise in both developing and mature markets.
Lora holds a degree in Pharmacy and a Master’s in Health Economics and Pharmacoeconomics, equipping her with a strong foundation for her work. She specializes in developing pricing, access, and reimbursement strategies throughout the product life cycle, from early product assessment to post-launch strategies. Additionally, she has been actively involved in the Joint Clinical Assessment (JCA) since the publication of the EU HTA regulation, focusing on anticipating the necessary changes for organizational readiness.
Articles: Lora Fleifel
EU Joint Clinical Assessments: Unlocking Europe’s Access Potential or Just More Red Tape?
Europe / Lora Fleifel, Director of Global Value Access & Pricing Operations Europe for Oncology at Merck, dissects the promise and pitfalls of the new EU Joint Clinical Assessment (JCA). The JCA aims to harmonise clinical evaluations to help reduce the significant disparities in patient access to innovative treatments that still exist across Europe. Yet, as Fleifel…
Latest Report
